Clinical Study On The Treatment Of Chronic Pulmonary Heart Disease Combined With Heart Failure(Qi Machine Imbalance,Blood Stasis And Water Withdrawal)

Objective:To observe the efficacy and safety of chronic pulmonary heart disease and blood activating disease combined with heart failure(qi disorder,stasis and water withdrawal),and to provide some reference for clinical treatment of pulmonary heart disease and heart failure.Methods:Selected from December 2021 to December 2022 in Shandong university of Chinese medicine hospital hospitalization,chronic pulmonary heart disease with heart failure diagnosis criteria,dialectical for qi disorders,stasis water of 64 patients,randomly divided into two groups,a group according to the guidelines for corresponding western medicine treatment as a control group,another group on the basis of western medicine treatment with the qi activating water prescription,two groups are treated for 2 weeks.After the treatment,the efficacy indicators and safety indicators of the two groups were collected and the changes were statistically analyzed.Results:1.Efficacy of cardiac function: The NYHA cardiac function grade of both groups improved compared with before(P <0.01),and the total response rate of the treatment group and the control group was 86.67% and 66.67%,respectively,which was statistically significant(P <0.05).2.Efficacy of Lee’s heart failure points: Lee’s heart failure points were evaluated after treatment,and the points decreased in both groups than before(P <0.01),and the total response rate of the treatment group and the control group was 86.67% and 66.67%,respectively,with statistical significance(P<0.05).3.Efficacy of TCM syndrome score: after treatment,the score of TCM syndrome in the two groups decreased compared with before(P <0.01),and the total response rate of the treatment group and control group was 90.00% and60.00%,respectively,with statistically significance(P <0.05).4.Efficacy of the six-minute walking test: When the six-minute walking test of both groups were evaluated after treatment,the walking distance increased compared with the previous group(P <0.01).The total response rate of the treatment and control groups was 83.33% and 60.00%,with statistical significance(P <0.05).5.Efficacy of type B brain natriuretic peptide precursor: the level of type B brain natriuretic peptide precursor decreased compared with the previous treatment(P <0.01),and between-group comparison,the type B brain natriuretic peptide precursor decreased significantly compared with the control group,statistically significant(P <0.05)6.Inflammation indicators: After treatment,the percentage of leukocytes,neutrophils and hypersensitive C-reactive protein in both groups decreased compared with the previous patients(P <0.01).Between the groups,the decrease in treatment indicators was more obvious,which was statistically significant(P <0.05).7.Safety analysis: There were no abnormalities in liver and kidney function,red blood cells,platelets and other indicators in the two groups before and after treatment,and no adverse reactions in both groups during treatment.Conclusion: On the basis of conventional western medicine joint treatment of chronic heart or pulmonary heart failure(qi disorders,blood stasis water syndrome)can effectively reduce the NYHA heart function classification,B brain natriuretic peptide precursor level,inflammation index,Lee’s heart failure integral,TCM syndrome integral,increase six minutes walk test distance,etc.,can effectively improve patients with clinical symptoms,signs,improve exercise endurance,enhance cardiopulmonary function,improve inflammation,than simple western medicine treatment better curative effect,safety is good.